Sun Phar­ma takes aim at a crowd­ed mar­ket with an­oth­er IL-23 pso­ri­a­sis drug from Mer­ck

In the last minute, late-stage race to the mar­ket with a new round of pso­ri­a­sis drugs, In­dia’s Sun Phar­ma­ceu­ti­cals is mak­ing its own bid with a new drug called tildrak­izum­ab. In-li­censed from Mer­ck, which agreed to han­dle the late-stage work for Sun for the for­mer MK-3222, it’s an­oth­er IL-23 drug, like J&J’s guselkum­ab.

But it didn’t per­form as well as the J&J drug in late-stage de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.